Humana Inc. has announced that it has exceeded its goals for the 2027 Medicare Advantage Star Ratings, a significant achievement that underscores the company's strong performance in the healthcare sector. This update is particularly important as it reflects Humana's competitive positioning within the hospital and medical service plans industry.
The company reported that it achieved Top Quartile results, defined as Stars revenue per member per month (PMPM) being 10% above the peer group median. Humana's President and Chief Executive Officer, Jim Rechtin, shared supplementary audio commentary about this achievement, which can be accessed on Humana’s Investor Relations page.
Humana's peer group includes notable competitors such as Centene, CVS, Elevance, HCSC, and United. The company's performance in the Medicare Advantage Star Ratings is critical as it affects revenue and member satisfaction, which are vital for maintaining market share in a competitive landscape.
According to the filing dated October 9, 2026, Humana has also affirmed its guidance of at least $9.00 in adjusted earnings per common share for the fiscal year ending December 31, 2026. This guidance aligns with previous announcements made in July and September of the same year, indicating a stable financial outlook.
In the filing, Humana emphasized that the Star Ratings are crucial for determining the quality of care provided and can impact the company's revenue through bonuses and rebates. The company intends to manage its product and benefit structure based on performance that approximates Top Quartile results, which is expected to yield benefits for 2028.
Looking ahead, Humana plans to hold a virtual investor update on December 10, 2026. This event will provide a mark to market against the framework established at its 2025 Investor Day, including initiatives expected to support earnings growth through 2028. The company aims to share more detailed information about its financial performance and strategic direction during this update.
Overall, Humana's recent achievements and affirmations in its earnings guidance suggest a robust operational framework, positioning the company favorably within the healthcare market. Stakeholders will be closely monitoring the developments as the company prepares for its upcoming investor update.